RxDoctor Payments Data

Alexander Johnson, MD

Hematology & Oncology · Bismarck, NDNPI 1275055956

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations.

$1,498in general payments, 2019–2025

Across 39 payments — averaging $38.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$195
  • Sanofi$171
  • Novartis$132
  • Blueprint Medicines Corporation$128
  • Pfizer$114
  • Eisai Inc.$103
  • plus $655 from 18 others

What the payments were for

  • Food & beverage$1,48299%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,498 in reported general payments places this provider in the 65th percentile of 35 hematology & oncology providers in North Dakota.

See all hematology & oncology providers in North Dakota

Medicare billing

Part B allowed, 2024
$91,092
Medicare patients
275
Services billed
864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate67$155,436
Imatinib Mesylate12$36,406
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen48$1,090
Anastrozole59$862
Dexamethasone86$819
Ondansetron Hcl61$517
Oxycodone Hcl20$409
Prednisone81$261
Pregabalin21$241
Letrozole15$212
Hydroxyurea18$206
Acyclovir17$198
Potassium Chloride12$184
ValacyclovirValacyclovir Hcl11$176
Lidocaine-PrilocaineLidocaine/Prilocaine17$164

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →